NEW YORK – Liquid biopsy firm Creatv MicroTech is developing a diagnostic platform that measures the amount and size of specific circulating stromal cells called cancer-associated macrophage-like cells (CAMLs) to identify traces of cancer in a patient’s bloodstream.
The Potomac, Maryland-based company initially plans to commercialize the method, called LifeTracDx, to predict immunotherapy response in stage II to III non-small cell lung cancer (NSCLC) cancer patients.
{iframe}https://www.360dx.com/cancer/creatv-microtech-aims-detect-patient-immune-cells-cancer-drug-response-prediction?utm_source=Sailthru&utm_mediu#.Xvz2IihKhPY{/iframe}